Data Insights
Artificial Intelligence (10)
Big Data (4)
Biosimilars (5)
Blockchain (1)
Cell & Gene Therapy (13)
Chemotherapy (1)
Cloud (1)
Corporate Governance (3)
Covid-19 (5)
Cybersecurity (4)
Digitalization (2)
Easy & Affordable (1)
Electronic Medical Record (EMR) Systems (1)
Environmental Sustainability (6)
Future of Work (2)
Genomics (10)
Health & Wellness (1)
Immuno-oncology (19)
Immunotherapy (1)
Internet of Things (2)
Microbiome (1)
Mobile Health (1)
Nanomedicine (2)
Oncology (4)
Orphan Designated Drugs (4)
Other Innovation Areas (87)
Precision and Personalized Medicine (1)
Remote Patient Monitoring (1)
Renewable Energy (1)
Robotics (2)
Small molecules (1)
Smart Hospitals (2)
Social Responsibility (3)
Virtual Care (3)
Showing 4 results out of 4
Q1 2024 update: mentions of orphan designated drugs in pharmaceutical industry filings
The global pharmaceutical industry experienced a 7% drop in company filings mentions of orphan designated drugs in Q1 2024 compared...
Q4 2023 update: orphan designated drugs related private equity activity in the pharmaceutical industry
Analysis of the key themes driving private equity deal activity reveals that orphan designated drugs accounted for 5 pharmaceutical deals...
Q4 2023 update: orphan designated drugs related M&A activity in the pharmaceutical industry
Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 30 pharmaceutical deals announced in...
Who’s posting what? Orphan Designated Drugs related social media posts increased by 9% in the pharma industry in Q1 2023
The global pharma industry experienced a 9% rise in social media posts on orphan designated drugs in Q1 2023 compared...